Molecular Analysis for Combination Therapy Choice

ComboMATCH is a large precision medicine initiative that is evaluating new combinations of anti-cancer drugs in selected groups of adults and children with cancer. The drug combinations are based on strong early evidence that they may be more effective than single therapy in treating some cancers. ComboMATCH consists of multiple treatment trials; participants will be assigned to treatment based on laboratory tests that look at the genes of their tumor cells. The drug combinations are either two targeted therapies together, or a targeted drug with chemotherapy. Each treatment trial has its own research goals, patient eligibility criteria, and enrollment timeline.

**ComboMATCH/EAY191 Eligibility Criteria***

- Locally advanced or metastatic solid tumors with measurable disease
- Must have progressed on at least one line of standard systemic therapy, OR have disease for which no standard treatment to prolong overall survival exists
- ECOG PS 0–2 OR Lansky/Karnofsky ≥ 50%
- ≥ 18 years old: tumor amenable to minimal risk biopsy and undergo a tumor biopsy to obtain samples for research, OR confirm availability of an archival FFPE tumor tissue specimen collected within 12 months prior to registration, without a complete/partial response to any intervening therapy
- < 18 years old: confirm willingness to submit of an archival FFPE tumor tissue specimen, if available, for research

*Refer to the protocol for complete eligibility details.

**ComboMATCH REGISTRATION Trial**

1. Standard of care genomic testing ordered at a Designated Lab (DL) by clinician
2. Physician identifies patient potentially eligible for ComboMATCH
3. Physician and patient choose ComboMATCH
4. Physician assesses brief registration protocol eligibility
5. Patient consents to registration trial
6. Site enrolls patient in OPEN with relevant clinical information†
7. MATCHBox uses genomic data from DL and clinical data from OPEN as part of algorithm to assign ComboMATCH treatment trial
8. Treatment trial assignment is provided to site

**ComboMATCH TREATMENT Trials**

1. Assess patient eligibility for treatment trial assignment
2. Patient consents to treatment trial and is enrolled in OPEN within 5 weeks of assignment
3. Treatment trial
4. Patient progresses
5. Pre-treatment tumor biopsy and plasma collection (or recent archival tissue)
6. Post-progression tumor biopsy and plasma collection

†Before enrolling a patient on EAY191, the site should plan to have the applicable Treatment Trial open, in order to avoid missing the 5-week window for enrollment.

ComboMATCH is led by the ECOG-ACRIN Cancer Research Group and National Cancer Institute, with treatment trials by the Alliance for Clinical Trials in Oncology, Children’s Oncology Group, NRG Oncology, and SWOG Cancer Research Network.

EAY191 Flowchart v.02/28/24